Novel agents may positively impact chemotherapy and transplantation in subsets of Diffuse Large B-cell Lymphoma.

This article reviews the treatment advances in DLBCL with novel and targeted agents that are aimed to improve efficacy especially in those with high-risk features. Expert opinion: Incorporation of novel therapies such as immunomodulatory agents and Bruton tyrosine kinase (BTK) inhibitors in treatment of higher-risk DLBCL subgroups have shown to be effective, however, confirmatory data are required to change the standard of care. While, autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD19-positive B-cells have revolutionized the outcomes of refractory DLBCL, the complexity of its production, post-infusion care, and the associated cost, currently has limited its use to select academic centers in the US. A multitude of other targeted agents and combinations, as well as cellular and immunotherapeutic agents are under investigation. PMID: 30884247 [PubMed - as supplied by publisher]
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research